Proteros generates structurally enabled, qualified hit and lead series to unlock challenging targets, de-risk early discovery programs, and accelerate the initiation of drug discovery projects. As a protein- and structure-centric company with deep expertise in protein science, structural biology, assays, biophysics, and screening, Proteros is uniquely positioned to execute successful hit identification (HitID) and hit-to-lead (H2L) campaigns. These capabilities are further strengthened by a differentiated portfolio of fragment and lead-like libraries and an extensive range of complementary screening technologies, including crystallography, SPR, ¹⁹F-NMR, mass spectrometry, enzymatic assays, reporter displacement assays, and complex formation assays.

Proteros has broad experience across diverse mechanisms of action, including inhibitors, activators, correctors, PPI blockers, destabilizers, molecular glues, RIPTACs, PROTACs, and allosteric, orthosteric, and covalent binders. Its expertise spans a wide range of target classes, including enzymes, RNA- and DNA-binding proteins, scaffolding proteins, transcription factors, and receptors. Particularly high success rates can be achieved through Proteros’ sophisticated crystallographic fragment screening (CFS) platform, which combines high-throughput structural screening with structure-based, one-step fragment expansion toward lead-like compounds. In parallel, Proteros operates one of the largest SPR facilities in the world, enabling library screening at HTS scale. Combined with proprietary data analysis workflows, this capability allows the identification of unique and actionable binders, including chemical matter that may be challenging to discover using conventional approaches.

Through this integrated combination of protein science, structural biology, biophysics, screening, and medicinal chemistry-enabling capabilities, Proteros identifies structurally enabled and trackable chemical matter that provides a strong foundation for advancing challenging targets and kick-starting early drug discovery programs.

High-resolution structures of challenging drug targets by X-ray crystallography and cryo-EM.

Proteros is a global leader in structure-based drug discovery, delivering more than 800 high-quality protein structures annually across 600+ protein targets, with 250+ targets with established crystallization systems available off-the-shelf through Gallery Mode. The company primarily provides protein-ligand co-crystal structures, tailored to accelerate medicinal chemistry and enable informed drug design.

Complementing its crystallography expertise, Proteros applies cryo-EM wherever it offers the better route to a structure, including large and flexible multiprotein assemblies, membrane proteins, and dynamic complexes. Feasibility assessment is completed in under a week, with structures delivered in roughly one month.

Together, these technologies address the industry’s most demanding target classes, including GPCRs, ion channels, transporters, helicases, RNA complexes, epigenetic targets (HDACs, BRDs, KDMs), nucleotide-binding proteins, small complexes down to ~50 kDa, and PROTAC and molecular glue ternary complexes. Across these challenging projects, Proteros achieves success rates exceeding 80%.

Notable structure determinations include PI3Kα, NLRP3, PKMYT1, and Werner helicase, alongside extensive expertise in biologics and antibody complexes, including Fab, nanobody (Nb), and other ternary assemblies.

The right protein for every downstream experiment, from construct design to full characterization.

Proteros brings together 70+ scientific experts with decades of experience in delivering high-quality proteins for the most challenging drug discovery targets. With more than 10,000 projects completed, 3,500+ purification runs per year on 85+ on-site ÄKTA systems, a >90% success rate for difficult targets, and 350+ targets with established production routes available in Gallery Mode, Proteros provides reliable access to fit-for-function proteins tailored to the needs of modern discovery programs.

From construct design, expression, and purification to advanced analytical characterization, all capabilities are integrated under one roof. The company’s expertise spans a broad range of challenging target classes, including membrane proteins (GPCRs, ion channels, and transporters), kinases, DNA/RNA-binding proteins, helicases, PROTAC and molecular glue targets, and RIPTAC-related proteins. Proteros also produces assembly-right biologics, including antibody fragments (Fab, Nb), as well as complex multi-protein assemblies, supported by comprehensive physicochemical and functional characterization.

A comprehensive suite of enzymatic and biophysical assays and screening technologies to identify binders and characterize ligand-target interactions with precision. Technologies include one of the largest SPR facilities in the world for true high-throughput SPR, a curated 186k library that can be screened in as little as two weeks, crystallographic fragment screening (CFS), ¹⁹F-NMR for fragment screening, mass spectrometry (ASMS and RapidFire) for covalent and non-covalent compounds screening, a suite of assays (reporter displacement assay, HTRF, nanoBRET) to address PPIs, PROTACs, and molecular glues, functional enzymatic assays across all major optical readouts, and thermal stability assays (nanoDSF and TSA) and a wide selection of orthogonal biophysical assays (ITC, MST, FP).

Curated libraries span a 190k centroid-based and 150k cluster-based collection, combinable into a single 345k non-covalent screen, a 4,100-compound covalent library, a 3,577-compound drug-repurposing set, and fragment collections matched to method: 3,000 for biophysical screening, 1,280 fluorinated for ¹⁹F-NMR, and 480 for CFS. Customer and third-party libraries can be screened as an alternative or in addition